Swiss biotech Oculis (Nasdaq: OCS) has appointed Björn Tackenberg as chief scientific officer, with an initial focus on ...

The Netherlands produces strong science. However, that is not enough to attract clinical studies to our country. Researchers, ...

Dutch gene therapy developer uniQure today announced the US Food and Drug Administration (FDA) has accepted for review the ...

October 2026 was a busy month for the US Food and Drug Administration (FDA). The agency approved two novel medicines, ...

Germany’s Fresenius has entered an exclusive development agreement with WuXi Biologics, a leading Chinese global contract ...

The Organization of Producers of India (OPPI) has emphasized the need for predictable regulatory policies, stronger ...

Fewer hospitalizations and more years of good health are not always reflected in the budget that pays for the drugs. This ...

US biotech companies Bambusa Therapeutics (Nasdaq: BBTX) and Aspen Neuroscience (Nasdaq: ASPE) have priced initial public ...

October produced 12 deals in The Pharma Letter ’s coverage, four of them worth more than $1 billion.

Israeli drugmaker Teva Industries said it will discontinue its Phase II TOPAS-MSA study of emrusolmin (TEV-‘286) in adults with multiple system atrophy (MSA), after an interim analysis indicated a ...

Norwegian health officials outlined efforts to reduce drug-related harm through shared patient records and updated prescribing guidance at an industry meeting that also examined the risks of ...

Henlius Biotech and Accord Healthcare have announced results from ASTRIDE, a randomized, open-label US bridging study of serplulimab (Hetronifly) in extensive-stage small cell lung cancer (ES-SCLC).